Tax

Most-read insurance stories in 2023 revealed

Like Cher, Insurance Post is turning back time to remember the industry Consumer Duty’s efforts, business interruption cases continuing to rumble on, developments at Direct Line, RSA’s personal lines exit, plus the other major insurance events of the…

Treasury haul from Insurance Premium Tax up 11%

UK PLC looks set to register yet another record annual Insurance Premium Tax haul as actuarial consultancy OAC reveals receipts for first eight months of 2023 are up 11% increase on the same period last year.

Failure to prevent insurance fraud is now a crime

Kennedy’s partners Hannah Williams and Iskander Fernandez explains how the Economic Crime and Corporate Transparency Act's ‘failure to prevent’ offence will be a game-changer for directors and officers insurers.

Top 75 MGAs: PIB Group

PIB Group’s main MGA-MGU activities dealing in UK-based non-life risks in 2022 were Citynet Underwriting Services, Let Alliance, Q Underwriting, Thistle Insurance Services and UKInsuranceNET, according to Insuramore.

Creditors set to lose out amid Plexus collapse

Documents show Plexus Group, which has entered administration, owes creditors about £21.5m, and that some are unlikely to receive the full payout, with most unlikely to receive anything at all.

Big Interview: ABI’s Mervyn Skeet

In his first big interview since being appointed director of general insurance policy at the Association of British Insurers, Mervyn Skeet speaks to Scott McGee about the reinsurance scheme for high-risk buildings and closing expectation and protection…

Consumers oblivious to IPT, survey reveals

A Consumer Intelligence survey commissioned by Insurance Post has shown that insurance premium tax is both poorly understood and unpopular, with only 30% of adults aware of its existence and 71% against the burden of the tax being passed on to consumers.

Intelligence: Insuring the growing US cannabis market

Last year Malta became the first European nation to legalise cannabis after the United Nations reclassified the drug to recognise its therapeutic uses and – with other EU countries looking to follow suit – Post spoke to the specialists striving to meet…

You need to sign in to use this feature. If you don’t have an Insurance Post account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here